Tezacaftor - Latest Advances

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.

Journal: International journal of molecular sciences

Published: October 10, 2025

Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis.

Journal: Therapeutic advances in respiratory disease

Published: October 09, 2025

Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: September 22, 2025

CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: September 19, 2025

Exposure of dams to Elexacaftor/ Tezacaftor/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: September 09, 2025

(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation.

Journal: American journal of physiology. Cell physiology

Published: September 08, 2025

Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients-a systematic review.

Journal: Frontiers in pediatrics

Published: August 19, 2025

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Journal: American journal of respiratory and critical care medicine

Published: August 11, 2025

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Journal: The Journal of clinical investigation

Published: August 07, 2025

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Journal: The Journal of clinical investigation

Published: August 07, 2025

Divergent Neurobehavioral Effects of CFTR Modulators Elexacaftor and Ivacaftor in Mice.

Journal: bioRxiv : the preprint server for biology

Published: July 09, 2025

Assessing CFTR Function and Epithelial Morphology in Human Nasal Respiratory Cell Cultures: A Combined Immunofluorescence and Electrophysiological Study.

Journal: International journal of molecular sciences

Published: July 02, 2025

Filters

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.

Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.

Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis.

Identification of early changes in multiple biomarkers following CFTR modulator initiation in patients with cystic fibrosis.

Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.

Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.

CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase.

CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase.

Exposure of dams to Elexacaftor/ Tezacaftor/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice.

Exposure of dams to Elexacaftor/ Tezacaftor/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice.

(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation.

(R)-vanzacaftor potentiates BKCa channels in the absence of CFTR correction or potentiation.

Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients-a systematic review.

Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients-a systematic review.

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Differential BK channel potentiation by vanzacaftor enantiomers enables therapy for modulator-ineligible people with cystic fibrosis.

Divergent Neurobehavioral Effects of CFTR Modulators Elexacaftor and Ivacaftor in Mice.

Divergent Neurobehavioral Effects of CFTR Modulators Elexacaftor and Ivacaftor in Mice.

Assessing CFTR Function and Epithelial Morphology in Human Nasal Respiratory Cell Cultures: A Combined Immunofluorescence and Electrophysiological Study.

Assessing CFTR Function and Epithelial Morphology in Human Nasal Respiratory Cell Cultures: A Combined Immunofluorescence and Electrophysiological Study.